Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia
Bogdan Popescu(University of California, San Francisco), Catherine C. Smith(University of California, San Francisco)
Cited by 1
Related Papers
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745
Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation
|The Lancet Infectious Diseases|2014|248
Crenolanib is a selective type I pan-FLT3 inhibitor
|Proceedings of the National Academy of Sciences|2014|211